Alzheimer's Disease: Risk Factors, Prevention, and Living Well
Alzheimer's disease is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. While there is currently no cure, research increasingly shows that up to 40% of Alzheimer's cases may be preventable through lifestyle modification — making proactive brain health measures among the most important investments you can make.
Written by
Dr. Sofia Martinez, PsyD
Brain & Cognitive Health
Medically reviewed by
Dr. Carlos Mendoza, MD
Board-Certified Neurologist
Key Takeaways
- Up to 40% of Alzheimer's cases may be preventable through lifestyle modification
- Managing blood pressure, blood sugar, and weight is among the most effective brain-protection strategies
- Aerobic exercise is the single most powerful brain-protective intervention available
- Sleep clears brain waste including amyloid-beta — 7–9 hours is essential for brain health
- The MIND diet reduced Alzheimer's risk by up to 53% in adherent participants
In This Article
Understanding Alzheimer's Disease
Alzheimer's is a progressive brain disorder that slowly destroys memory, thinking skills, and eventually the ability to carry out basic daily activities. The disease is characterized by the accumulation of two abnormal protein deposits in the brain: amyloid plaques (clumps of beta-amyloid protein between neurons) and tau tangles (twisted fibers of tau protein inside neurons). These deposits disrupt neural communication and trigger inflammation that progressively damages brain cells. The disease typically develops over 20 years before symptoms appear, with a prolonged preclinical phase during which intervention may be most effective. The hippocampus — critical for memory formation — is typically the first region affected, explaining why memory loss is usually the first noticeable symptom.
Modifiable Risk Factors — What You Can Control
A landmark 2020 Lancet Commission identified 12 modifiable risk factors that collectively account for approximately 40% of Alzheimer's cases worldwide. These include: hearing loss in midlife (the largest modifiable risk factor, accounting for 8% of cases); traumatic brain injury; physical inactivity; depression; smoking; social isolation; hypertension; diabetes; obesity; heavy alcohol consumption; air pollution; and limited education/cognitive engagement. This means that aggressive management of cardiovascular risk factors — blood pressure, blood sugar, cholesterol, weight, and smoking — is one of the most powerful strategies for brain protection. What's good for the heart is profoundly good for the brain: vascular health directly affects brain perfusion, neuronal nutrition, and waste clearance.
Brain-Protective Lifestyle Strategies
Exercise is arguably the most powerful brain-protective intervention. Aerobic exercise increases brain-derived neurotrophic factor (BDNF) — a protein that supports neuron growth, connection, and survival — and has been shown to increase hippocampal volume. The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) combines the Mediterranean and DASH diets with specific emphasis on brain-healthy foods: leafy greens, nuts, berries, beans, olive oil, and fish. A clinical trial found the MIND diet reduced Alzheimer's risk by up to 53% in strict adherents. Sleep is when the brain's glymphatic system clears toxic waste including amyloid-beta — chronic sleep deprivation significantly accelerates amyloid accumulation. Cognitive engagement through learning, social interaction, and mentally challenging activities builds cognitive reserve that provides resilience against Alzheimer's pathology.
Current Treatments and Emerging Therapies
Two classes of medications are currently approved for Alzheimer's symptom management. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) boost levels of acetylcholine, a neurotransmitter involved in memory and thinking; they modestly slow symptom progression in mild-to-moderate Alzheimer's. Memantine regulates glutamate activity and is approved for moderate-to-severe stages. In 2023, lecanemab (Leqembi) became the first disease-modifying therapy to receive traditional FDA approval — it removes amyloid plaques and modestly slows cognitive decline in early-stage disease, though with a risk of brain swelling. Donanemab showed similar results in phase III trials. These represent significant scientific milestones, marking the beginning of an era where the underlying disease biology can be targeted rather than just managing symptoms.
